Research programme: cellspan organ implants - Biostage/Mayo Clinic

Drug Profile

Research programme: cellspan organ implants - Biostage/Mayo Clinic

Alternative Names: Cellspan bronchial implant; Cellspan oesophageal implant; Cellspan tracheal implant

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Biostage
  • Developer Biostage; Mayo Clinic
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Apr 2017 Biostage plans to apply for Orphan Drug status for cellspan oesophageal implant in Europe
  • 06 Apr 2017 Pharmacodynamic results from a preclinical trial in Cancer released by Biostage
  • 16 Mar 2017 Biostage plans first-in-human clinical trials in Oesophageal cancer in USA before the end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top